Palmitoyl-glucosamine co-micronized with curcumin for maintenance of meloxicam-induced pain relief in dogs with osteoarthritis pain

BMC Veterinary Research

Research

Maria Federica della Valle¹  Maria Beatrice Conti²  Giorgia della Rocca²  Alessandra Di Salvo²  Carlo Schievano³ 

[1] CeDIS (Centro di Documentazione e Informazione Scientifica), Innovet Italia SRL, Via Leonardo da Vinci 3, 35030, Saccolongo, Italy;Department of Veterinary Medicine, Centro Di Ricerca Sul Dolore Animale (CeRiDA), Università Degli Studi Di Perugia, 06123, Perugia, Italy;Innovative Statistical Research SRL, Prato Della Valle 24, 35123, Padua, Italy;

关键词: Osteoarthritis;    Dogs;    Chronic pain;    ALIAmide;    Palmitoyl-glucosamine;    Curcumin;    Meloxicam;    Non-steroidal anti-inflammatory drugs;    Multimodal analgesia;   

DOI  :  10.1186/s12917-023-03594-4

 received in 2022-08-03, accepted in 2023-01-27,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundOsteoarthritis (OA) pain is the number one cause of chronic pain in dogs. Multimodal treatment, including combining safe and effective nutritional interventions with non-steroidal anti-inflammatory drugs (NSAIDs), is currently considered one of the most appropriate choices for managing OA pain. Palmitoyl-glucosamine is a feed material belonging to the ALIAmide family, whose parent molecule is the prohomeostatic lipid amide N-palmitoyl-ethanolamine. Curcumin is a promising plant antioxidant. The present study aimed at investigating whether 18-week dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain pain relief in dogs with OA-associated chronic pain receiving meloxicam (1.5 mg/ml oral suspension) on a tapering regimen (progressive 25% decrease of the original 0.1 mg/kg/day dose, on a biweekly basis) during the first 8 weeks of treatment. Pain was assessed both by the owners and veterinary surgeons, with the first using both subjective evaluation and validated metrology instruments—i.e., Helsinki Chronic Pain Index (HCPI) and Canine Brief Pain Inventory (CBPI)—while the second rating the severity of lameness and pain on palpation on two previously used 5-point scales.ResultsA total of fifty-eight dogs with OA chronic pain entered the uncontrolled study. Pain on HCPI was considered severe at baseline (range 18–39). Based on owner’s assessment, 90% of dogs who responded to meloxicam at the full-dose regimen could reduce meloxicam up to 25% of the original dose without experiencing pain worsening. Moreover, 75% of dogs was assessed as having no pain increase ten weeks after meloxicam withdrawal. A statistically significant decrease of pain severity as scored by HCPI (P < 0.0001) was observed two and ten weeks after meloxicam withdrawal compared to study entry (17.0 ± 1.05 and 15.1 ± 1.02, respectively, vs 29.0 ± 0.74; mean ± SEM). After meloxicam withdrawal, no statistically significant change in the CBPI scores was recorded. Pain on palpation and lameness significantly changed to less severe distributions along the study period (P < 0.0001).ConclusionThe findings appear to suggest that dietary integration with palmitoyl-glucosamine co-micronized with curcumin was able to maintain meloxicam-induced pain relief in dogs with severe OA chronic pain.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 5

Fig. 1

40854_2023_458_Article_IEq119.gif